Opinion: Market share isn’t the only metric for biosimilars’ success
Market share is often held up as the most relevant metric for the success of a biosimilar class. I believe there are other metrics, like cost savings or signs of …
Read MoreTag: Biosimilars
Opinion: Biosimilars competition helps patients more than generic competition
Much of the current drug-pricing agenda proposed by President Biden and by Congress is based on the belief that greater government control — rather than free market competition — is …
Read More
Opinion: FDA’s naming rule for biosimilars has undermined Congress and health care
I recently tried to order white blood cell growth factor (pegfilgrastim) biosimilar for one of my patients. This is a drug that helps prevent fever and infection associated with low …
Read More
Virtual Event: The evolving landscape for biosimilars
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET. Biosimilars were anticipated to be a solution to the soaring cost of prescription medicines to …
Read More
Biosimilar drugs gain ground in U.S., but concerns linger about when patients can switch
It took years for Elle Moxley to get a diagnosis that explained her crippling gastrointestinal pain and digestion problems, fatigue and hot, red rashes. But even after learning in 2016 …
Read More
Opinion: The FDA just broke the logjam on interchangeable biologics. Here’s what that decision means
The Food and Drug Administration’s decision on Wednesday to approve a long-acting insulin called Semglee (insulin glargine-yfgn) as the first interchangeable biologic licensed for the U.S. market represents a major …
Read More